Developer docs
API playgroundTry for free, no card

Search company profiles

GLD Partners, LP

Full company profile

uuid000a83p

Namestring
GLD Partners, LP
Legal namestring
GLD Partners, LP
Websiteurl
gldlp.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

GLD Partners, LP is a Los Angeles-based private investment partnership founded in 2003 that operates as a life sciences-focused portfolio builder in the biotechnology sector. Rather than pursuing a traditional fund model, the firm acquires distressed and de-risked biotech assets and builds platform-driven biotech companies. Its strategy centers on capital-efficient acquisition of late-stage clinical programs with existing safety data and leveraging proprietary technologies through licensing arrangements.

The company's portfolio includes three principal assets as of October 2025. First, through a Chapter 11 Section 363 sale in the U.S. Bankruptcy Court for the Southern District of New York, GLD acquired Seelos Therapeutics' late-stage ketamine program for major depressive disorder (targeting a market projected to exceed $15 billion annually by 2035) and a trehalose program for rare neurodegenerative diseases (with orphan drug designation potential). GLD had previously acquired Seelos' senior secured debt, which provided negotiating leverage in the asset acquisition. Second, in October 2025, GLD launched Altagenics, a wholly-owned biotechnology subsidiary focused on drug discovery for muscle-wasting diseases (sarcopenia and cachexia), which leverages Heligenics' proprietary GigaAssay™ functional genomics platform capable of testing hundreds of thousands of protein variants in parallel.

GLD Partners generates value through clinical advancement and eventual commercialization of its acquired and launched programs rather than through traditional product sales or fee-based revenue. The firm operates with 1-10 employees and uses GlobeNewswire press releases and industry press coverage as its primary visibility channels. Daniel Gordon serves as Managing Director. There are no disclosed revenue figures, funding rounds, or pricing models in the available data, consistent with the firm's structure as a private investment partnership building long-term biotech equity value rather than generating near-term cash flow.

Short descriptiontext

GLD Partners is a Los Angeles-based private life sciences investment partnership that acquires distressed biotech assets and builds platform-driven biotech companies, with a current portfolio spanning CNS, rare neurodegenerative, and muscle-wasting disease programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
life sciences investment, biopharmaceutical asset acquisition, drug development programs, alternative investments, biotech company creation
Industry3 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAKAIAO
Neurogenetics & Rare Neurologic Diseases
SECONDARYHLAJADAF
Clinical Trials Authorization & Oversight (GCP)
Healthcare & Life Sciences/Public Health, Government & Regulators/Medicines & Healthcare Product Regulators (Drugs/Biologics/Devices)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Portfolio Management and Investment Advice523940
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Investment Advice6282
Product category
Biopharmaceutical Investment
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

GLD Partners, LP is a private life sciences investment firm that acquires distressed and de-risked biopharmaceutical assets and builds platform-driven biotech companies. The firm targets CNS, rare disease, and muscle-wasting therapeutic areas, currently holding a Phase 3-ready ketamine program for major depressive disorder, a trehalose program for rare neurodegenerative diseases, and Altagenics (a biotech using Heligenics' GigaAssay™ platform for muscle-wasting disease drug discovery).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Global MDD therapeutics market projected to exceed $15 billion annually by 2035
+1 more record
Product overview1 text field

GLD Partners, LP is a life sciences investment firm operating as a portfolio company builder. The company acquires distressed biotech assets through Chapter 11 proceedings and builds platform-driven biotech companies. Current portfolio includes: the ketamine program for major depressive disorder and trehalose program for rare neurodegenerative diseases (both acquired from Seelos Therapeutics), and Altagenics (newly launched company focused on muscle-wasting diseases using the GigaAssay™ functional genomics platform). The firm targets CNS, rare disease, and muscle-wasting therapeutic areas with capital-efficient development strategies.

Product and service3 records
1Altagenics
CategoryBiotechnology company / Drug discovery platform
Description

A biotechnology company launched by GLD Partners focused on drug discovery for muscle-wasting diseases, leveraging Heligenics' proprietary GigaAssay™ functional genomics platform. Initially targeting sarcopenia and cachexia.

2Ketamine Program
CategoryClinical program (CNS therapeutics)
Description

A late-stage ketamine clinical program targeting major depressive disorder (MDD), acquired from Seelos Therapeutics. GLD plans to advance this program into Phase 3 clinical trials.

3Trehalose Program
CategoryClinical program (rare disease therapeutics)
Description

A trehalose clinical program targeting rare neurodegenerative disorders, acquired from Seelos Therapeutics. Features orphan drug designation opportunities. GLD plans to advance this program into adaptive Phase 2/3 clinical trials.

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-21
Description

GLD Partners acquired select assets from Seelos Therapeutics through a Chapter 11 Section 363 sale in the U.S. Bankruptcy Court for the Southern District of New York. GLD had previously acquired Seelos' senior secured debt. Acquired assets include late-stage ketamine program for major depressive disorder and trehalose program for rare neurodegenerative disorders. GLD plans to advance both programs into Phase 3 and adaptive Phase 2/3 clinical trials respectively.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-07
Description

GLD Partners launched Altagenics as a new biotech company leveraging Heligenics' proprietary GigaAssay™ platform for drug discovery. The platform enables testing hundreds of thousands of protein variants in parallel, representing a core technology for Altagenics' muscle-wasting disease programs targeting sarcopenia and cachexia. This represents GLD's strategy to build platform-driven biotech companies using licensed proprietary technology.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Royalty Pharma is the largest dedicated pharma royalty and alternative-investment firm, acquiring cash-flow interests in late-stage biopharma assets. Highly comparable to GLD's strategy of acquiring de-risked pharma assets through alternative transaction structures.

2Baker Bros. Advisors
TypeDirect peer
Description

Baker Bros. is a long-only biotech-focused investment firm that takes concentrated positions in life sciences companies. Directly comparable as a life sciences-focused alternative investment manager with similar late-stage asset underwriting expertise.

TypeDirect peer
Description

BridgeBio is a commercial-stage biotech company builder with a portfolio model across multiple therapeutic areas including CNS and rare disease. Comparable as a multi-program biotech builder, though structured as a public operating company rather than an LP.

TypeDirect peer
Description

Perceptive Advisors is a life sciences-focused investment firm managing credit and equity strategies across biotech. Comparable as a private life sciences investment manager deploying capital into biotech assets.

TypeDirect peer
Description

OrbiMed is one of the largest dedicated healthcare investment firms globally, with venture, growth, and credit strategies across therapeutics. Comparable as a healthcare-focused alternative investment manager with deep biotech expertise.

TypeDirect peer
Description

ARCH Venture Partners creates and invests in biotech companies, often founding platform companies around proprietary technologies — directly comparable to GLD's launch of Altagenics around the licensed GigaAssay™ platform.

TypeDirect peer
Description

RA Capital is a healthcare-focused investment manager that combines public equity and private investment, often participating in late-stage biotech rounds. Comparable as a dedicated life sciences alternative investment firm.

TypeDirect peer
Description

Deerfield Management is a healthcare investment firm deploying capital across public equities, private debt, and venture. Comparable as a healthcare-focused alternative asset manager with multi-strategy biotech exposure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GLD Partners, LP

Biopharmaceutical Investmentgldlp.com

GLD Partners is a Los Angeles-based private life sciences investment partnership that acquires distressed biotech assets and builds platform-driven biotech companies, with a current portfolio spanning CNS, rare neurodegenerative, and muscle-wasting disease programs.

What GLD Partners, LP does

GLD Partners, LP is a Los Angeles-based private investment partnership founded in 2003 that operates as a life sciences-focused portfolio builder in the biotechnology sector. Rather than pursuing a traditional fund model, the firm acquires distressed and de-risked biotech assets and builds platform-driven biotech companies. Its strategy centers on capital-efficient acquisition of late-stage clinical programs with existing safety data and leveraging proprietary technologies through licensing arrangements.

The company's portfolio includes three principal assets as of October 2025. First, through a Chapter 11 Section 363 sale in the U.S. Bankruptcy Court for the Southern District of New York, GLD acquired Seelos Therapeutics' late-stage ketamine program for major depressive disorder (targeting a market projected to exceed $15 billion annually by 2035) and a trehalose program for rare neurodegenerative diseases (with orphan drug designation potential). GLD had previously acquired Seelos' senior secured debt, which provided negotiating leverage in the asset acquisition. Second, in October 2025, GLD launched Altagenics, a wholly-owned biotechnology subsidiary focused on drug discovery for muscle-wasting diseases (sarcopenia and cachexia), which leverages Heligenics' proprietary GigaAssay™ functional genomics platform capable of testing hundreds of thousands of protein variants in parallel.

GLD Partners generates value through clinical advancement and eventual commercialization of its acquired and launched programs rather than through traditional product sales or fee-based revenue. The firm operates with 1-10 employees and uses GlobeNewswire press releases and industry press coverage as its primary visibility channels. Daniel Gordon serves as Managing Director. There are no disclosed revenue figures, funding rounds, or pricing models in the available data, consistent with the firm's structure as a private investment partnership building long-term biotech equity value rather than generating near-term cash flow.

GLD Partners, LP firmographics

Firmographics
Name
GLD Partners, LP
Legal name
GLD Partners, LP
Website
https://gldlp.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
1–10 employees
Short description
GLD Partners is a Los Angeles-based private life sciences investment partnership that acquires distressed biotech assets and builds platform-driven biotech companies, with a current portfolio spanning CNS, rare neurodegenerative, and muscle-wasting disease programs.
Ownership category
akta.pro rank

GLD Partners, LP industry classification

Industry
Product category
Biopharmaceutical Investment
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Portfolio Management and Investment Advice (523940)
SIC
Pharmaceutical Preparations (2834), Investment Advice (6282)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAKAIAO
Neurogenetics & Rare Neurologic Diseases
SECONDARYHLAJADAF
Clinical Trials Authorization & Oversight (GCP)
Healthcare & Life Sciences/Public Health, Government & Regulators/Medicines & Healthcare Product Regulators (Drugs/Biologics/Devices)

Keywords

  • Life sciences investment
  • Biopharmaceutical asset acquisition
  • Drug development programs
  • Alternative investments
  • Biotech company creation

Where GLD Partners, LP is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Markets served

GLD Partners, LP business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Marketing channels2 records

GLD Partners, LP product offering

Product offering

Core offering

GLD Partners, LP is a private life sciences investment firm that acquires distressed and de-risked biopharmaceutical assets and builds platform-driven biotech companies. The firm targets CNS, rare disease, and muscle-wasting therapeutic areas, currently holding a Phase 3-ready ketamine program for major depressive disorder, a trehalose program for rare neurodegenerative diseases, and Altagenics (a biotech using Heligenics' GigaAssay™ platform for muscle-wasting disease drug discovery).

Product overview

GLD Partners, LP is a life sciences investment firm operating as a portfolio company builder. The company acquires distressed biotech assets through Chapter 11 proceedings and builds platform-driven biotech companies. Current portfolio includes: the ketamine program for major depressive disorder and trehalose program for rare neurodegenerative diseases (both acquired from Seelos Therapeutics), and Altagenics (newly launched company focused on muscle-wasting diseases using the GigaAssay™ functional genomics platform). The firm targets CNS, rare disease, and muscle-wasting therapeutic areas with capital-efficient development strategies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Altagenics A biotechnology company launched by GLD Partners focused on drug discovery for muscle-wasting diseases, leveraging Heligenics' proprietary GigaAssay™ functional genomics platform. Initially targeting sarcopenia and cachexia.
  • Ketamine Program A late-stage ketamine clinical program targeting major depressive disorder (MDD), acquired from Seelos Therapeutics. GLD plans to advance this program into Phase 3 clinical trials.
  • Trehalose Program A trehalose clinical program targeting rare neurodegenerative disorders, acquired from Seelos Therapeutics. Features orphan drug designation opportunities. GLD plans to advance this program into adaptive Phase 2/3 clinical trials.

Quantifiable outcome

  • Global MDD therapeutics market projected to exceed $15 billion annually by 2035
  • +1 more outcomes

Companies that use GLD Partners, LP

Customer profile

Segments1 record

Ideal customer profiles1 record

GLD Partners, LP technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

GLD Partners, LP partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Seelos Therapeutics, Inc.coreStrategic or Co-development Partner · 21 October 2025GLD Partners acquired select assets from Seelos Therapeutics through a Chapter 11 Section 363 sale in the U.S. Bankruptcy Court for the Southern District of New York. GLD had previously acquired Seelos' senior secured debt. Acquired assets include late-stage ketamine program for major depressive disorder and trehalose program for rare neurodegenerative disorders. GLD plans to advance both programs into Phase 3 and adaptive Phase 2/3 clinical trials respectively.
  • HeligenicscoreTechnology or Integration · 7 October 2025GLD Partners launched Altagenics as a new biotech company leveraging Heligenics' proprietary GigaAssay™ platform for drug discovery. The platform enables testing hundreds of thousands of protein variants in parallel, representing a core technology for Altagenics' muscle-wasting disease programs targeting sarcopenia and cachexia. This represents GLD's strategy to build platform-driven biotech companies using licensed proprietary technology.

Recent moves5 records

Expansion highlights5 records

GLD Partners, LP competitors and assessment

Company assessment

Direct peers

  • Royalty Pharma: Royalty Pharma is the largest dedicated pharma royalty and alternative-investment firm, acquiring cash-flow interests in late-stage biopharma assets. Highly comparable to GLD's strategy of acquiring de-risked pharma assets through alternative transaction structures.
  • Baker Bros. Advisors: Baker Bros. is a long-only biotech-focused investment firm that takes concentrated positions in life sciences companies. Directly comparable as a life sciences-focused alternative investment manager with similar late-stage asset underwriting expertise.
  • BridgeBio Pharma: BridgeBio is a commercial-stage biotech company builder with a portfolio model across multiple therapeutic areas including CNS and rare disease. Comparable as a multi-program biotech builder, though structured as a public operating company rather than an LP.
  • Perceptive Advisors: Perceptive Advisors is a life sciences-focused investment firm managing credit and equity strategies across biotech. Comparable as a private life sciences investment manager deploying capital into biotech assets.
  • OrbiMed: OrbiMed is one of the largest dedicated healthcare investment firms globally, with venture, growth, and credit strategies across therapeutics. Comparable as a healthcare-focused alternative investment manager with deep biotech expertise.
  • ARCH Venture Partners: ARCH Venture Partners creates and invests in biotech companies, often founding platform companies around proprietary technologies — directly comparable to GLD's launch of Altagenics around the licensed GigaAssay™ platform.
  • RA Capital Management: RA Capital is a healthcare-focused investment manager that combines public equity and private investment, often participating in late-stage biotech rounds. Comparable as a dedicated life sciences alternative investment firm.
  • Deerfield Management: Deerfield Management is a healthcare investment firm deploying capital across public equities, private debt, and venture. Comparable as a healthcare-focused alternative asset manager with multi-strategy biotech exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key highlights5 records

Customer concentration

GLD Partners, LP social profiles

Digital presence

GLD Partners, LP financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GLD Partners, LP leadership team

Management profile

Number of profiles

Profiles1 record

GLD Partners, LP subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

GLD Partners, LP funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GLD Partners, LP M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GLD Partners, LP

What does GLD Partners, LP do?

GLD Partners, LP is a private life sciences investment firm that acquires distressed and de-risked biopharmaceutical assets and builds platform-driven biotech companies. The firm targets CNS, rare disease, and muscle-wasting therapeutic areas, currently holding a Phase 3-ready ketamine program for major depressive disorder, a trehalose program for rare neurodegenerative diseases, and Altagenics (a biotech using Heligenics' GigaAssay™ platform for muscle-wasting disease drug discovery).

Is GLD Partners, LP a public or private company?

GLD Partners, LP is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was GLD Partners, LP founded?

GLD Partners, LP was founded in 2003. It employs 1 to 10 people.

Where is GLD Partners, LP based?

GLD Partners, LP is headquartered in Los Angeles, United States, in the North America region.

Who are GLD Partners, LP's main competitors?

Direct peers on record are Royalty Pharma, Baker Bros. Advisors, BridgeBio Pharma, Perceptive Advisors, OrbiMed, ARCH Venture Partners, RA Capital Management and Deerfield Management.

Does GLD Partners, LP have an API?

No public API is recorded for GLD Partners, LP.

What industry is GLD Partners, LP in?

GLD Partners, LP's product category is Biopharmaceutical Investment. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAKAIAO, Neurogenetics & Rare Neurologic Diseases. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SalesTech StarGLD Partners, LP Acquires Seelos Therapeutics, Inc. Assets, Strengthening GLD’s Growing Life Sciences PortfolioGLD Partners, LP has completed the acquisition of select assets from Seelos Therapeutics, Inc. through a Chapter 11 Section 363 sale in the U.S. Bankruptcy Court for the Southern District of New York, having previously acquired Seelos' senior secured debt. The acquired portfolio includes late-stage ketamine and trehalose programs targeting major depressive disorder and rare neurodegenerative diseases, which GLD views as capital-efficient additions to its CNS and rare disease pipeline. GLD plans to advance both programs into Phase 3 and adaptive Phase 2/3 clinical trials, respectively, leveraging existing safety data with enhanced study design and regulatory strategy.GlobeNewswireGLD Partners, LP Acquires Seelos Therapeutics, Inc. Assets, Strengthening GLD’s Growing Life Sciences PortfolioGLD Partners, LP completed the acquisition of select assets from Seelos Therapeutics, Inc. through a Section 363 sale in the U.S. Bankruptcy Court for the Southern District of New York, having previously acquired Seelos' senior secured debt. The transaction includes Seelos' late-stage ketamine program for major depressive disorder and trehalose program for rare neurodegenerative disorders, which GLD plans to advance through Phase 3 and adaptive Phase 2/3 trials respectively. The ketamine program targets a global MDD therapeutics market projected to exceed $15 billion annually by 2035, while the trehalose program addresses a multibillion-dollar rare disease space with orphan drug designation opportunities.GlobeNewswireGLD Partners LP Launches New Biotech Company, Altagenics, to Accelerate Drug Discovery for Muscle-Wasting DiseasesGLD Partners LP announced the launch of Altagenics, a new biotechnology company focused on drug discovery for muscle-wasting diseases, leveraging Heligenics' proprietary GigaAssay™ platform. The company will initially target sarcopenia and cachexia using next-generation functional genomics technology capable of testing hundreds of thousands of protein variants in parallel. This venture represents GLD Partners' strategy to build platform-driven biotech companies, with plans to replicate this scalable model across additional therapeutic areas.PR NewswireGLD Partners, LP Forms Investment Fund to Focus on Urban Renewal OpportunitiesGLD Partners, LP, a Los Angeles-based investment firm, has launched GLD Urban Renewal Fund I, LLC, a new investment fund focused on mixed-use and multi-family investment opportunities in urban renewal areas across US cities. The fund aims to build a portfolio of more than 10,000 multi-family units by 2025, targeting cities with populations exceeding 100,000 that have established municipal redevelopment strategies. The fund will pursue a combination of real estate acquisitions and investments in debt and equity securities, adhering to environmentally conscious management standards.PR NewswireGLD Partners, LP to Donate Medical Supplies to Support COVID-19 Treatment EffortsGLD Partners, LP, a Los Angeles-based investment firm, announced on April 13, 2020, that it will redirect its international factories in Southeast Asia and North Africa to produce medical masks, gowns, and related equipment for COVID-19 treatment efforts in the United States. Initial shipments were expected to begin by April 12, 2020, with all manufactured items to be donated at no cost to hospitals and medical centers in Southern California. The firm stated it has already suspended prior production orders to prioritize the medical supply production.